title: Multi-factor dimensionality reduction applied to a large prospective investigation on gene-gene and gene-environment interactions.
abstract: It is becoming increasingly evident that single-locus effects cannot explain complex multifactorial human diseases like cancer. We applied the multi-factor dimensionality reduction (MDR) method to a large cohort study on gene-environment and gene-gene interactions. The study (case-control nested in the EPIC cohort) was established to investigate molecular changes and genetic susceptibility in relation to air pollution and environmental tobacco smoke (ETS) in non-smokers. We have analyzed 757 controls and 409 cases with bladder cancer (n=124), lung cancer (n=116) and myeloid leukemia (n=169). Thirty-six gene variants (DNA repair and metabolic genes) and three environmental exposure variables (measures of air pollution and ETS at home and at work) were analyzed. Interactions were assessed by prediction error percentage and cross-validation consistency (CVC) frequency. For lung cancer, the best model was given by a significant gene-environment association between the base excision repair (BER) XRCC1-Arg399Gln polymorphism, the double-strand break repair (DSBR) BRCA2-Asn372His polymorphism and the exposure variable 'distance from heavy traffic road', an indirect and robust indicator of air pollution (mean prediction error of 26%, P<0.001, mean CVC of 6.60, P=0.02). For bladder cancer, we found a significant 4-loci association between the BER APE1-Asp148Glu polymorphism, the DSBR RAD52-3'-untranslated region (3'-UTR) polymorphism and the metabolic gene polymorphisms COMT-Val158Met and MTHFR-677C>T (mean prediction error of 22%, P<0.001, mean CVC consistency of 7.40, P<0.037). For leukemia, a 3-loci model including RAD52-2259C>T, MnSOD-Ala9Val and CYP1A1-Ile462Val had a minimum prediction error of 31% (P<0.001) and a maximum CVC of 4.40 (P=0.086). The MDR method seems promising, because it provides a limited number of statistically stable interactions; however, the biological interpretation remains to be understood.
authors.affiliation: ISI Foundation, Torino Italy.
authors.forename: M
authors.initials: M
authors.lastname: Manuguerra
authors.forename: G
authors.initials: G
authors.lastname: Matullo
authors.forename: F
authors.initials: F
authors.lastname: Veglia
authors.forename: H
authors.initials: H
authors.lastname: Autrup
authors.forename: A M
authors.initials: AM
authors.lastname: Dunning
authors.forename: S
authors.initials: S
authors.lastname: Garte
authors.forename: E
authors.initials: E
authors.lastname: Gormally
authors.forename: C
authors.initials: C
authors.lastname: Malaveille
authors.forename: S
authors.initials: S
authors.lastname: Guarrera
authors.forename: S
authors.initials: S
authors.lastname: Polidoro
authors.forename: F
authors.initials: F
authors.lastname: Saletta
authors.forename: M
authors.initials: M
authors.lastname: Peluso
authors.forename: L
authors.initials: L
authors.lastname: Airoldi
authors.forename: K
authors.initials: K
authors.lastname: Overvad
authors.forename: O
authors.initials: O
authors.lastname: Raaschou-Nielsen
authors.forename: F
authors.initials: F
authors.lastname: Clavel-Chapelon
authors.forename: J
authors.initials: J
authors.lastname: Linseisen
authors.forename: H
authors.initials: H
authors.lastname: Boeing
authors.forename: D
authors.initials: D
authors.lastname: Trichopoulos
authors.forename: A
authors.initials: A
authors.lastname: Kalandidi
authors.forename: D
authors.initials: D
authors.lastname: Palli
authors.forename: V
authors.initials: V
authors.lastname: Krogh
authors.forename: R
authors.initials: R
authors.lastname: Tumino
authors.forename: S
authors.initials: S
authors.lastname: Panico
authors.forename: H B
authors.initials: HB
authors.lastname: Bueno-De-Mesquita
authors.forename: P H
authors.initials: PH
authors.lastname: Peeters
authors.forename: E
authors.initials: E
authors.lastname: Lund
authors.forename: G
authors.initials: G
authors.lastname: Pera
authors.forename: C
authors.initials: C
authors.lastname: Martinez
authors.forename: P
authors.initials: P
authors.lastname: Amiano
authors.forename: A
authors.initials: A
authors.lastname: Barricarte
authors.forename: M J
authors.initials: MJ
authors.lastname: Tormo
authors.forename: J R
authors.initials: JR
authors.lastname: Quiros
authors.forename: G
authors.initials: G
authors.lastname: Berglund
authors.forename: L
authors.initials: L
authors.lastname: Janzon
authors.forename: B
authors.initials: B
authors.lastname: Jarvholm
authors.forename: N E
authors.initials: NE
authors.lastname: Day
authors.forename: N E
authors.initials: NE
authors.lastname: Allen
authors.forename: R
authors.initials: R
authors.lastname: Saracci
authors.forename: R
authors.initials: R
authors.lastname: Kaaks
authors.forename: P
authors.initials: P
authors.lastname: Ferrari
authors.forename: E
authors.initials: E
authors.lastname: Riboli
authors.forename: P
authors.initials: P
authors.lastname: Vineis
mesh_terms: D018432:Drug Resistance, Multiple; D006801:Humans; D009369:Neoplasms / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D011336:Probability; D011446:Prospective Studies